CHRNA7 and psoriasis: To evaluate the effect of CAP on IMQ-induced psoriasis, PNU-282987 (PNU-282987), a selective α7nAChR agonist, was injected intraperitoneally (10 mg/kg) 1 h prior to the daily IMQ treatment for 6 days.